常见可变免疫缺陷
医学
CD38
CD8型
淋巴增殖性病變
免疫分型
C-C趋化因子受体7型
免疫学
T细胞
CD19
流式细胞术
内科学
白细胞介素2受体
胃肠病学
淋巴瘤
免疫系统
抗体
趋化因子
干细胞
趋化因子受体
生物
川地34
遗传学
作者
N. Lanio,E. Sarmiento,A. Gallego,Javier Carbone
出处
期刊:Allergologia et immunopathologia
[Codon Publications]
日期:2009-02-01
卷期号:37 (1): 14-20
被引量:20
标识
DOI:10.1016/s0301-0546(09)70246-0
摘要
A system based on the B-cell phenotype has recently been proposed to classify patients suffering from common variable immunodeficiency (CVID). Immunophenotypic T-cell abnormalities have also been correlated with clinical findings, although they have never been used in classification strategies.To simultaneously assess T and B-cell subset abnormalities in CVID patients and their relationship with clinical findings. To identify potential immunophenotypic T-cell abnormalities that could be further evaluated in multicenter studies.Peripheral blood lymphocytes from 21 CVID patients and 21 healthy donors were stained for T and B-cell subsets, analyzed by flow cytometry, and correlated with clinical characteristics.Patients classified as MB0 (CD19/CD27+ < 11 %) showed higher percentages of CD4/ CD45RA (87 % vs 67 %, p = 0.028) and lower percentages of CD8/CD45RA+CCR7+ (10 % vs 26 %, p = 0.028) and CD4/CD25+ T-cells (36 % vs 62 %, p = 0.034) than MB2 patients. Even though our cohort was small, we observed a higher prevalence of distinct clinical complications of CVID in patients with B and T-cell abnormalities. Nonmalignant lymphoproliferative disorders and IgG hypercatabolism were more frequently observed in MB0 patients. A higher prevalence of splenomegaly was observed among CVID patients with increased levels of CD4/CD45RA, activated CD4/CD38+DR+, CD8/DR+, and CD8/CD38+ T-cells, as well as in those with lower percentages of CD4/CD45RA+CCR7+ and CD4/CD25+ T-cells. Lymphoproliferative disorders were more prevalent among CVID patients with higher CD4/CD45RA percentages.The study of T-cell subsets warrants further evaluation as a potential tool to better identify CVID patients with distinct clinical profiles.
科研通智能强力驱动
Strongly Powered by AbleSci AI